公开(公告)号：US20230172920A1

公开(公告)日：2023-06-08

申请号：US17996616

申请日：2021-04-19

申请人： Novartis AG

发明人： Astrid JULLION ,  Christophe MEILLE ,  Cornelia QUADT ,  Michael John ROY ,  Marion WIESMANN

IPC分类号： A61K31/4439 ,  A61P25/28

CPC分类号： A61K31/4439 ,  A61P25/28

摘要： The present disclosure relates to the field of pharmacy, particularly to a CSF-1R inhibitor for use in the treatment of disease modulated by CSF-1R. For example, the disclosure relates to a CSF-1R inhibitor for use in the treatment of cancer or neurodegenerative diseases. The disclosure also relates to a CSF-1R inhibitor or a pharmaceutical combination comprising a CSF-1R inhibitor, or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody molecule, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer; to a method for the treatment of cancer that involves administering a CSF-1R inhibitor or the combination; and to the use of a CSF-1R inhibitor or the combination for the manufacture of a medicament for the treatment of cancer.